Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS/pMMR colorectal cancer: a randomized phase 2 trial
Feng Wang(Sun Yat-sen University), Rui‐Hua Xu(Sun Yat-sen University), Weijia Fang(Zhejiang Cancer Hospital), Jibin Li(State Key Laboratory of Pollution Control and Resource Reuse), Min Wang(Sun Yat-sen University), Zixian Wang(Sun Yat-sen University), Ying Jin(Harbin Medical University), Qi Zhao(Academy of Medical Sciences), Yan‐Xing Chen(Sun Yat-sen University), Yanqiao Zhang(Harbin Medical University), Wen‐Long Guan(Sun Yat-sen University), Miao‐Zhen Qiu(Sun Yat-sen University), Yuhong Li(Southwest Jiaotong University), Lulu Liu(Second Affiliated Hospital of Zhejiang University), Zhi‐Qiang Wang(Nanjing University of Chinese Medicine), Feng‐Hua Wang(Sun Yat-sen University), Chao Ren(Sun Yat-sen University), Hui Luo(Sun Yat-sen University), Lin Tian(Harbin Medical University), Xiaohua Hu(Guangxi Medical University), Yingnan Wang(Sun Yat-sen University), Run-Jie Huang(Sun Yat-sen University), Dong‐Sheng Zhang(Sun Yat-sen University), Wenting Liao(Sun Yat-sen University), De‐Shen Wang(Sun Yat-sen University)
Cited by 162
Related Papers
Circular RNA: metabolism, functions and interactions with proteins
|Molecular Cancer|2020|1.6k
IBS: an illustrator for the presentation and visualization of biological sequences
|Bioinformatics|2015|1.1k
Gemcitabine and Cisplatin Induction Chemotherapy in Nasopharyngeal Carcinoma
|New England Journal of Medicine|2019|934
METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma
|Molecular Cancer|2019|868